Discovery of Sulforaphane as an Inducer of Ferroptosis in U-937 Leukemia Cells: Expanding Its Anticancer Potential.
anticancer activity
apoptosis
ferroptosis
natural products
necroptosis
non-canonical cell death
sulforaphane
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
received:
10
11
2021
revised:
16
12
2021
accepted:
21
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
In recent years, natural compounds have emerged as inducers of non-canonical cell death. The isothiocyanate sulforaphane (SFN) is a well-known natural anticancer compound with remarkable pro-apoptotic activity. Its ability to promote non-apoptotic cell-death mechanisms remains poorly investigated. This work aimed to explore the capacity of SFN to induce non-apoptotic cell death modalities. SFN was tested on different acute myeloid leukemia cell lines. The mechanism of cell death was investigated using a multi-parametric approach including fluorescence microscopy, western blotting, and flow cytometry. SFN triggered different cell-death modalities in a dose-dependent manner. At 25 μM, SFN induced caspase-dependent apoptosis and at 50 μM ferroptosis was induced through depletion of glutathione (GSH), decreased GSH peroxidase 4 protein expression, and lipid peroxidation. In contrast, necroptosis was not involved in SFN-induced cell death, as demonstrated by the non-significant increase in phosphorylation of receptor-interacting protein kinase 3 and phosphorylation of the necroptotic effector mixed lineage kinase domain-like pseudokinase. Taken together, our results suggest that the antileukemic activity of SFN can be mediated via both ferroptotic and apoptotic cell death modalities.
Identifiants
pubmed: 35008240
pii: cancers14010076
doi: 10.3390/cancers14010076
pmc: PMC8750507
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Brain Korea (BK21) FOUR and the Creative-Pioneering Researchers Program
ID : 370C-20160062
Organisme : National Research Foundation (NRF)
ID : 019R1A2C-1009231
Références
Carcinogenesis. 2004 Feb;25(2):219-27
pubmed: 14578157
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Mol Biol Rep. 2018 Dec;45(6):2491-2499
pubmed: 30350234
Nutr Cancer. 2005;52(2):213-24
pubmed: 16201852
Food Funct. 2018 May 23;9(5):2589-2606
pubmed: 29701207
Eur J Nutr. 2008 May;47 Suppl 2:73-88
pubmed: 18458837
Cell Death Discov. 2016 Oct 03;2:16065
pubmed: 27752362
ESMO Open. 2018 Feb 2;3(2):e000285
pubmed: 29464109
Free Radic Res. 2011 Oct;45(10):1136-42
pubmed: 21749318
Mol Nutr Food Res. 2018 Sep;62(18):e1700965
pubmed: 29468815
Cancers (Basel). 2021 Jan 15;13(2):
pubmed: 33467668
Food Chem Toxicol. 2014 Feb;64:157-65
pubmed: 24296129
PLoS One. 2014 Jun 09;9(6):e99391
pubmed: 24910998
Vascul Pharmacol. 2007 Feb;46(2):77-84
pubmed: 16938492
Theranostics. 2021 Mar 4;11(10):4759-4769
pubmed: 33754026
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1439-1448
pubmed: 29936713
Leukemia. 2003 Jan;17(1):120-4
pubmed: 12529668
Biol Res. 2019 Jul 18;52(1):37
pubmed: 31319879
Cells. 2019 Nov 21;8(12):
pubmed: 31766571
Cancer Chemother Pharmacol. 2011 May;67(5):1167-78
pubmed: 20689952
Front Oncol. 2020 Apr 01;10:393
pubmed: 32296637
Biochem Pharmacol. 2004 Sep 15;68(6):1133-8
pubmed: 15313410
Int J Oncol. 2014 Oct;45(4):1497-506
pubmed: 24993616
Nat Protoc. 2006;1(6):3159-65
pubmed: 17406579
PLoS One. 2014 Mar 25;9(3):e92980
pubmed: 24667842
Biotechnol Adv. 2014 Nov 1;32(6):1123-32
pubmed: 24699435
Cell Death Dis. 2013 Sep 19;4:e804
pubmed: 24052072
Mini Rev Med Chem. 2016;16(12):980-95
pubmed: 26586127
Chem Biol Interact. 2013 Sep 25;205(2):119-27
pubmed: 23811387
Biomed Pharmacother. 2008 Nov;62(9):637-44
pubmed: 18313257
Drug Des Devel Ther. 2018 Sep 11;12:2905-2913
pubmed: 30254420
Blood. 2008 Mar 15;111(6):3173-82
pubmed: 18192505
Biomark Res. 2020 Oct 2;8:50
pubmed: 33024562
Cell Mol Life Sci. 2002 Nov;59(11):2004-12
pubmed: 12530531
Trends Endocrinol Metab. 2019 Jun;30(6):335-346
pubmed: 31060881
Biomed Res Int. 2015;2015:402386
pubmed: 26185755
Mutat Res. 2007 May-Jun;635(2-3):90-104
pubmed: 17134937
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33188036
Mol Cancer Ther. 2007 Mar;6(3):1013-21
pubmed: 17339367
Biomol Ther (Seoul). 2016 May 1;24(3):320-7
pubmed: 27098859
Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103
pubmed: 25936818
Cancer Cell. 2019 Jun 10;35(6):830-849
pubmed: 31105042
J Xray Sci Technol. 2010;18(3):293-308
pubmed: 20714087
J Nutr. 2004 Sep;134(9):2229-36
pubmed: 15333709
ACS Chem Biol. 2018 Apr 20;13(4):1013-1020
pubmed: 29512999
Oncol Lett. 2021 Jan;21(1):71
pubmed: 33365082
Mol Cell. 2019 Jan 17;73(2):354-363.e3
pubmed: 30581146
Cell Death Dis. 2020 Feb 3;11(2):88
pubmed: 32015325
Oxid Med Cell Longev. 2014;2014:360438
pubmed: 24999379
Onco Targets Ther. 2020 Jun 11;13:5429-5441
pubmed: 32606760
Mutat Res. 2010 Jul 7;689(1-2):65-73
pubmed: 20510253
Mol Med Rep. 2017 Jan;15(1):331-338
pubmed: 27959410
Leukemia. 2018 May;32(5):1135-1146
pubmed: 29472718
Toxicol In Vitro. 2015 Aug;29(5):1026-33
pubmed: 25882683
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251